Sector News

AstraZeneca to cut nearly 100 jobs at U.K. site as efficiencies ‘hammer’ workers

March 28, 2019
Life sciences

Less than two years after revealing a multimillion-dollar upgrade plan for its plant in Macclesfield, U.K., AstraZeneca is cutting back, slashing almost 100 jobs in what local union called a “hammer blow” to U.K. manufacturing.

AstraZeneca will let go of 94 employees—out of a total of around 1,800—at the Macclesfield facility in Cheshire, according to GMB Union, which said the cut wouldn’t take place until 2020. The Macclesfield site, which makes medicines such as legacy prostate cancer drug Zoladex, is AZ’s second largest manufacturing facility.

The layoff isn’t necessarily a bad reflection on AZ’s business. It follows a $50 million investment the British drugmaker made there on packaging. Following the upgrade, AZ said its efficiency has increased significantly, and according to GMB, that means fewer employees are needed.

The workers’ union depicted the company’s decision as “a hammer blow for manufacturing in the North West—and the U.K. as a whole,” said GMB Organizer Stephen Boden in a statement.

Like others, AZ has been rethinking its global manufacturing network. Earlier this year, AZ unveiled plans to shutter two plants in Boulder and Longmont, Colorado, and lay off 210 workers stationed there as part of a plan to streamline its biologics supply chain and consolidate the biologics manufacturing network at a large-scale facility in Frederick, Maryland.

AZ also has put investments in U.K. manufacturing on hold as Brexit uncertainty clouds the entire U.K. economic outlook. Last October, AZ Chairman Leif Johansson told France’s Le Monde that the company “will maintain our decision not to invest” if Brexit future remains unclear, according to Reuters.

AZ has two other operations in Cheshire, including the Alderley Park R&D center—whose functions and employees are being moved to the new Cambridge, U.K., campus—and a vaccine research team at Speke, near Liverpool. It’s not clear whether jobs at those sites will be affected, and AZ hasn’t immediately responded to a FiercePharma request for confirmation.

Meanwhile, construction of AZ’s new Cambridge headquarters has suffered repeated delays and has reportedly gone over budget. In its 2018 annual report, the company said it’s expected to start occupation of the building from 2020 rather than have it fully operational in that year as previously reported.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend